ClinicalTrials.gg
RecruitingNCT07710014Updated Oct 7, 2026

Evaluation of Foquest in Adults 65 Years and Older With ADHD

A Phase 4 interventional study of Methylphenidate hydrochloride extended-release capsules in Attention Deficit Hyperactivity Disorder, sponsored by Dar Clinical Research Inc.. Recruiting at 1 site in Canada. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Dar Clinical Research Inc. · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 7, 2026Now RecruitingFirst site in Canada+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 181 studies testing methylphenidate in Attention Deficit Disorder with Hyperactivity — 19 open to participants now, 21 under way, 1 of them phase 3. Methylphenidate · Attention Deficit Disorder with Hyperactivity.

Planned enrollment
123rd of 179
36 · median 68
Started
2026
with 4 others
Phase 4
87 of 181
13 open now
Primary completion
2027-07
later than 12 of 20 live
Registered
180th of 181
by date

Among the 181 studies testing methylphenidate in Attention Deficit Disorder with Hyperactivity, this one is the 123rd largest by planned enrollment of the 179 interventional ones that give a count, is one of 5 that started in 2026, is one of 87 in phase 4, reaches primary completion later than 12 of the 20 other live ones, and was the 180th registered.

Attention Deficit Disorder with Hyperactivity

1,821 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 297 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

19 of the 181 studies testing methylphenidate in Attention Deficit Disorder with Hyperactivity are open now, in 7 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About methylphenidate

Methylphenidate: first FDA approval 1955 (RITALIN), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 200 Attention Deficit Disorder with Hyperactivity studies recruiting now, 26 (13%) set no upper age limit and 169 (85%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 181 studies testing methylphenidate in Attention Deficit Disorder with Hyperactivity, or all of them as a file.
02

Study summary

This study is evaluating the safety and effectiveness of Foquest (multilayer-release methylphenidate), a once-daily extended-release medication for attention-deficit/hyperactivity disorder (ADHD), in adults aged 65 years and older.

ADHD can persist into older age and is associated with reduced quality of life and difficulties with executive function. Foquest is currently approved in Canada for the treatment of ADHD in adults up to age 65, but there is very limited research on its use in older adults. People over 65 may respond differently to stimulant medications due to age-related changes in how the body processes drugs, other medical conditions, and increased sensitivity to cardiovascular side effects.

This is an open-label study, meaning all participants will know they are receiving the study medication. There is no placebo group. Participants will take Foquest once daily for approximately 10 weeks, including a 6-week dose adjustment period, a 2-week maintenance period, and a 2-week follow-up period. The dose will start at 25 mg daily and may be increased weekly up to a maximum of 100 mg daily based on how well the participant responds and tolerates the medication.

The main goal of the study is to measure changes in ADHD symptoms using a clinician-rated scale called the Adult ADHD Investigator Symptom Rating Scale (AISRS). The study will also assess changes in executive function, overall clinical improvement, and cardiovascular safety measures including blood pressure, heart rate, and electrocardiograms (ECGs). Safety will be closely monitored throughout the study, with enhanced cardiovascular monitoring during the first 6 weeks of treatment.

Read the detailed description

This is a prospective, open-label, within-subject (pre-post), investigator-initiated Phase IV trial evaluating the safety and efficacy of Foquest (multilayer-release methylphenidate hydrochloride; MLR-MPH) in adults aged 65 years and older with a DSM-5 diagnosis of ADHD.

Background: Foquest is a once-daily oral stimulant consisting of a 20% immediate-release outer layer and an 80% delayed-release core, with onset of effect within approximately 1 hour and duration of up to 16 hours. It is approved by Health Canada for ADHD in adults up to age 65. The product monograph acknowledges that data are lacking for individuals above this age. Pharmacoepidemiologic evidence (Tadrous et al., 2021) suggests a transient increase in cardiovascular risk during the first 30 days of stimulant initiation in adults aged 66 and older, underscoring the need for careful cardiac screening and monitoring in this population.

Study Design: Each participant will be involved for approximately 10 weeks, comprising a 6-week dose titration phase, a 2-week maintenance phase, and a 2-week follow-up period. Participants will attend 5 in-person visits and 4 phone visits. Foquest will be initiated at 25 mg daily (or an investigator-selected dose based on prior medication history) and titrated weekly to a maximum of 100 mg daily based on efficacy and tolerability.

Cardiovascular Safety Monitoring: Enhanced cardiovascular monitoring is incorporated based on published evidence of early cardiovascular risk with stimulant initiation in older adults. Blood pressure and heart rate are measured in triplicate at screening and assessed at all in-person visits. Twelve-lead ECGs are performed at screening, baseline, Week 3, Week 5, and end of treatment (Week 8). Predefined criteria for treatment interruption include sustained resting heart rate greater than 100 bpm, systolic blood pressure greater than 180 mmHg, or diastolic blood pressure greater than 110 mmHg. Immediate discontinuation criteria include blood pressure at or above 180/120 mmHg, new arrhythmia, or symptoms suggestive of acute cardiovascular or cerebrovascular events.

Primary Endpoint: Mean change from baseline (Week 1) to end of treatment (Week 8) in AISRS total score, analyzed using a paired t-test in the modified intention-to-treat population.

Secondary Endpoints: Change from baseline to Week 8 in ASRS-5 total score, CGI-S score, BRIEF-A Global Executive Composite T-score, and distribution of CGI-I scores at Week 8. Cardiovascular parameters (systolic and diastolic blood pressure, heart rate, QTcF interval) and adverse events will be analyzed as safety endpoints.

Sample Size: 36 participants are planned, allowing for up to 15% attrition to ensure 30 completers, providing 80% power to detect a within-subject effect size of Cohen's d of 0.53 or greater.

This study addresses a critical evidence gap regarding the pharmacological treatment of ADHD in older adults and aims to inform evidence-based prescribing decisions for this underserved population.

03

Conditions studied

  • Attention Deficit Hyperactivity Disorder

Keywords

  • ADHD
  • Methylphenidate
  • Foquest
  • Geriatric
  • Extended-Release Stimulant
  • Attention Deficit Disorder
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged 65 years or older at the time of consent.
  2. Mentally and physically competent to provide and willing to comply with the study protocol
  3. Meets criteria for ADHD combined presentation, inattentive presentation, or hyperactive/impulsive presentation based on clinical history
  4. SRS-5 score of 14 or greater at screening
  5. AISRS total score of 24 or greater at baseline
  6. (MoCA) score of 26 or greater

Exclusion criteria

Exclusion Criteria:

  1. Satisfied with current ADHD treatment
  2. History of myocardial infarction, arrhythmia, or congenital heart disease
  3. Mean systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 100 mmHg measured in triplicate at screening despite treatment
  4. Treated hypertension not stable on medication or with dose changes in the last 30 days
  5. History of or stroke
  6. Current or lifetime diagnosis of bipolar I or II disorder, cyclothymic disorder, or bipolar disorder not otherwise specified
  7. Clinical history strongly suggestive of undiagnosed bipolar spectrum disorder
  8. Active suicidal ideation or behavior per C-SSRS at screening
  9. Current substance use disorder
  10. History of drug or alcohol abuse in the last 10 years as defined by DSM-5 criteria for substance use disorder (moderate or severe)
  11. True allergy to methylphenidate, history of serious adverse reactions to methylphenidate, or known non-response to methylphenidate
  12. History of seizure disorder other than a single childhood febrile seizure before age 3
  13. History of glaucoma, hyperthyroidism, thyrotoxicosis, advanced arteriosclerosis, or severe renal insufficiency ( less than 30 mL/min/1.73 m²)
  14. Use of a monoamine oxidase inhibitor currently or within the past 14 days
  15. Abnormal baseline including left ventricular hypertrophy or greater than 450 ms (males) or greater than 470 ms (females)
  16. History of heart failure, unexplained dyspnea on exertion, or newly identified murmur
  17. score less than 26 or evidence of cognitive impairment
  18. Currently considered a suicide risk in the opinion of the investigator
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Foquest (Multilayer-Release Methylphenidate)

    All participants receive open-label Foquest (multilayer-release methylphenidate hydrochloride) once daily, initiated at 25 mg and titrated weekly over 6 weeks to an optimal dose up to a maximum of 100 mg daily, followed by a 2-week maintenance phase and a 2-week follow-up period.

    Drug: Methylphenidate hydrochloride extended-release capsules

Interventions

  • DrugMethylphenidateStudies of MethylphenidateMethylphenidate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Once-daily oral extended-release methylphenidate capsule with multilayer-release technology (20% immediate-release outer layer, 80% delayed-release core). Starting dose 25 mg daily, titrated weekly over 6 weeks to optimal dose (maximum 100 mg daily) based on efficacy and tolerability. Capsules taken in the morning, swallowed whole or opened and sprinkled on applesauce or yogurt. Available strengths: 25, 35, 45, 55, 70, 85, and 100 mg. Two-week maintenance at optimal dose followed by 2-week follow

    Also known as: Foquest, MLR-MPH

06

What researchers measure

Primary outcomes

  1. Mean Change in Adult ADHD Investigator Symptom Rating Scale (AISRS) Total Score

    Mean change from baseline (Week 1) to end of treatment (Week 8) in AISRS total score. The AISRS is an 18-item clinician-administered scale aligned with DSM criteria for ADHD, with each item rated 0-3 (total score range 0-54). Higher scores indicate greater symptom severity. Analysis uses a paired t-test in the modified intention-to-treat population.

    Time frame: Baseline (Week 1) to End of Treatment (Week 8)

Secondary outcomes

  1. Mean Change in ASRS-5 Total Score

    Mean change from baseline to Week 8 in the Adult ADHD Self-Report Scale version 1.1 (ASRS-5) total score. The ASRS-5 is an 18-item self-report questionnaire with Part A (Inattention) and Part B (Hyperactivity/Impulsivity), items rated 0 (Never) to 4 (Very Often). Analyzed using paired t-test and repeated-measures ANOVA across post-baseline timepoints (Weeks 3, 5, and 8).

    Time frame: Baseline (Week 1) to Week 8, with interim assessments at Weeks 3 and 5

  2. Mean Change in Clinical Global Impression - Severity (CGI-S) Score

    Mean change from baseline to Week 8 in CGI-S score. The CGI-S is a 7-point clinician-rated scale of overall illness severity (1 = Normal, not at all ill; 7 = Among the most extremely ill patients). A responder analysis will report the proportion of participants achieving CGI-S score of 3 or less (mildly ill or better) at Week 8.

    Time frame: Baseline (Week 1) to Week 8

  3. Clinical Global Impression - Improvement (CGI-I) Responder Rate

    Distribution of CGI-I scores at Week 8. The CGI-I is a 7-point clinician-rated scale evaluating change from baseline (1 = Very much improved; 7 = Very much worse). The clinical responder rate is defined as the proportion of participants rated as much improved or very much improved (CGI-I score of 2 or less) at Week 8, reported with 95% exact binomial confidence intervals.

    Time frame: Week 8 (End of Treatment)

  4. Mean Change in BRIEF-A Global Executive Composite (GEC) T-Score

    Mean change from baseline to Week 8 in the Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A) Global Executive Composite T-score. The BRIEF-A is a 75-item self-report measure of executive functioning in adults aged 18-90, producing norm-referenced T-scores. Higher scores indicate greater executive dysfunction. Individual index scores (Behavioral Regulation Index, Metacognition Index) will also be analyzed.

    Time frame: Baseline (Week 1) to Week 8

  5. Change in Systolic Blood Pressure

    Mean change from baseline to Week 8 in resting systolic blood pressure (mmHg). Assessed at in-person visits at Weeks 0, 3, 5, and 8. Outlier criteria: systolic BP greater than 140 mmHg or increase greater than 20 mmHg from baseline.

    Time frame: Baseline (Week 1) to Week 8, with interim assessments at Weeks 3 and 5

  6. Incidence of Treatment-Emergent Adverse Events

    Incidence of treatment-emergent adverse events (TEAEs) summarized by system organ class and preferred term using MedDRA coding. TEAEs tabulated by severity (mild, moderate, severe) and relationship to study medication. Serious adverse events, adverse events leading to dose modification, and adverse events leading to discontinuation reported separately.

    Time frame: From first dose of study medication to 14 days after study completion (approximately 10 weeks)

  7. Columbia-Suicide Severity Rating Scale (C-SSRS) Changes

    C-SSRS data summarized at each visit using frequency and percentage of participants in each suicidal ideation severity category (0-5), shift tables showing treatment-emergent changes from baseline (new onset or worsening of suicidal ideation category), and incidence of any suicidal behavior events.

    Time frame: Baseline (Week 1) through End of Study/Follow-Up (Week 10), assessed at every study visit

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Wakamatsu A, Nomura S, Tate Y, Shimizu S, Harada Y. Effects of methylphenidate hydrochloride on the cardiovascular system in vivo and in vitro: a safety pharmacology study. J Pharmacol Toxicol Methods. 2009 May-Jun;59(3):128-34. doi: 10.1016/j.vascn.2009.01.003. Epub 2009 Mar 9. PubMed 19281853 ↗
  • Tadrous M, Shakeri A, Chu C, Watt J, Mamdani MM, Juurlink DN, Gomes T. Assessment of Stimulant Use and Cardiovascular Event Risks Among Older Adults. JAMA Netw Open. 2021 Oct 1;4(10):e2130795. doi: 10.1001/jamanetworkopen.2021.30795. PubMed 34694389 ↗
  • Parasrampuria DA, Schoedel KA, Schuller R, Silber SA, Ciccone PE, Gu J, Sellers EM. Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users. J Clin Psychopharmacol. 2007 Oct;27(5):459-67. doi: 10.1097/jcp.0b013e3181515205. PubMed 17873677 ↗
  • Michielsen M, Kleef D, Bijlenga D, Zwennes C, Dijkhuizen K, Smulders J, Hazewinkel A, Beekman ATF, Kooij JJS. Response and Side Effects Using Stimulant Medication in Older Adults With ADHD: An Observational Archive Study. J Atten Disord. 2021 Oct;25(12):1712-1719. doi: 10.1177/1087054720925884. Epub 2020 Jun 8. PubMed 32508213 ↗
  • Godfrey J. Safety of therapeutic methylphenidate in adults: a systematic review of the evidence. J Psychopharmacol. 2009 Mar;23(2):194-205. doi: 10.1177/0269881108089809. Epub 2008 May 30. PubMed 18515459 ↗
  • Garcia-Argibay M, Burkner PC, Lichtenstein P, Zhang L, D'Onofrio BM, Andell P, Chang Z, Cortese S, Larsson H. Methylphenidate and Short-Term Cardiovascular Risk. JAMA Netw Open. 2024 Mar 4;7(3):e241349. doi: 10.1001/jamanetworkopen.2024.1349. PubMed 38446477 ↗
  • Adler LA, Orman C, Starr HL, Silber S, Palumbo J, Cooper K, Berwaerts J, Harrison DD. Long-term safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: an open-label, dose-titration, 1-year study. J Clin Psychopharmacol. 2011 Feb;31(1):108-14. doi: 10.1097/JCP.0b013e318203ea0a. PubMed 21192153 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Jul 2027, 9 months after the start.

Of 44 non-industry phase 4 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 81. This study's planned 9 months is below that.

Counting every sponsor, half of 62 studies reached it within 38 months; a quarter within 18 and three quarters within 70.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Oct 2026, on Oct 7, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2026
First posted
Jul 17, 2026
StartActual
Oct 6, 2026was Jul 2026
Primary completionEst.
Jul 21, 2027
CompletionEst.
Jul 21, 2027
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 7, 2026
Sites
1 site added — first site in Canada
Show site
  • DAR Clinical Research Inc. · Ottawa, Canada
Oct 7, 2026
Start date
Jul 2026→Oct 6, 2026 (actual)
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Canada
    Show site
    • DAR Clinical Research Inc. · Ottawa, Canada
    Start date Jul 2026→Oct 6, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07710014
Lead sponsor
Dar Clinical Research Inc.
Responsible party
Sponsor
First posted
Jul 17, 2026
Start date
Oct 6, 2026
Primary completion
Jul 21, 2027 (estimated)
Completion
Jul 21, 2027 (estimated)
Last update
Oct 7, 2026

Study contacts

Judy van Stralen, M.D, FRCPC
Contact
judy@cfpe.ca
613-726-7355 ext. 101
Doron Almagor, MD, FRCPC
Contact
doron.almagor@possibilitiesclinic.com
613-726-7355 ext. 101
Judy van Stralen, MD, FRCPC
principal investigator · JPM van Stralen Medicine Professional Corporation / DAR Clinical Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methylphenidate

Start the discussion